Imaging-based Phenotypic Screening is a extremely powerful and flexible approach to drug discovery and pre-clinical research.
Learn how imaging-based phenotypic assays work and what kind of information you can expect from working with us.
WHAT ARE SOME OF THE CHALLENGES ASSOCIATED WITH PHENOTYPIC ASSAYS?
Time to develop imaging-based assays and especially those involving difficult to culture human primary and iPS-derived cells can often be longer than a similar ELISA-based assay. We are specialists in developing imaging-based assays, it is all we do. We have industry-experienced staff with strong academic backgrounds. Most of all, we listen to our clients. These factors taken together with our strategy to develop directly in 384-well plates means that we can develop a prototype assay from scratch and generate high quality data faster than any other service provider.
Phenotypic assays that use imaging, specifically automated quantitative fluorescence microscopy or high content screening (HCS), bring their own set of challenges. We’ve tried to address how we tackle these challenges but if you have other concerns please contact us.